PORTFOLIO
MANAGEMENT
ONESTOP AGENCY
From product idea to internationally scalable portfolio
A key objective of portfolio management is to identify, from the multitude of available TCM formulas and phyto-products from China, those that are internationally viable. This involves not only medical efficacy but also a product's ability to overcome regulatory, industrial, and commercial hurdles. Tasly Germany's OneStop Agency utilizes structured evaluation models that combine qualitative TCM expertise with quantitative criteria. Traditional application logic, modern pharmacological insights, safety data, and market feedback are systematically integrated. Furthermore, the portfolio is actively developed through reformulations, expanded indications, new dosage forms, and alternative market strategies. Portfolio management is therefore not a static selection process but a dynamic management tool that enables long-term value creation for our partners.
Building a pipeline together
At Tasly Germany, building a joint product pipeline is understood as a reciprocal process between the Chinese and European markets. On the one hand, there is the systematic selection of suitable TCM formulas and phyto-products from China that have the potential to meet European regulatory, industrial, and market-related requirements. On the other hand, Tasly Germany supports European partners in adapting their existing product portfolios for successful positioning in the Chinese market. In both directions, medical concepts, regulatory frameworks, manufacturing standards, and market logics are integrated early on. This results in an integrated product pipeline that does not serve individual markets in isolation, but rather strategically leverages interfaces, pools development efforts, and prepares market entries. The pipeline is continuously reviewed and further developed – as a long-term platform for sustainable international value creation.
Targeted for international markets
Successful product development requires that target markets be considered concretely, not abstractly. Tasly EU consistently aligns product strategies with specific market requirements – from regulatory approval pathways and reimbursement and pricing logics to medical application practices and distribution channels. Different market mechanisms in Europe and China are not standardized, but rather specifically considered and strategically translated. This results in products and portfolios that are not only formally eligible for approval, but also remain compatible with the respective healthcare systems. Market alignment is not an afterthought, but an integral part of product and pipeline development – a prerequisite for planned market entries and sustainable commercial implementation.
